International Clinical Trial: A Single-Center, Randomized, Blinded, Controlled Phase II Clinical Trial Evaluating the Safety, Tolerability, and Pharmacodynamics of Recombinant Human Anti-Rabies Virus Monoclonal Antibody Injection in Healthy Population

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119961) titled 'A Single-Center, Randomized, Blinded, Controlled Phase II Clinical Trial Evaluating the Safety, Tolerability, and Pharmacodynamics of Recombinant Human Anti-Rabies Virus Monoclonal Antibody Injection in Healthy Population' on March 6.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Wuhan Infectious Disease Hospital

Condition: Rabies

Intervention: Monotherapy Group 1:40 IU/kg monoclonal antibody, intramuscular injection on the outer thigh on day 0 Monotherapy Group 2:80 IU/kg monoclonal antibody group, intramuscular injection on the outer thigh on day 0 Monotherapy Group 3:20IU/kg ...